Subscribe to RSS
DOI: 10.1055/s-0037-1603766
Pulmonary Sarcoidosis
Publication History
Publication Date:
27 July 2017 (online)
![](https://www.thieme-connect.de/media/srccm/201704/lookinside/thumbnails/10-1055-s-0037-1603766_01299-1.jpg)
Abstract
Sarcoidosis is a systemic granulomatous disorder of unknown etiology, with a predilection for the respiratory system, involved in more than 90% of cases, with considerable variability in terms of patterns and prognostic implications. A protean interplay between genetic susceptibility and antigen exposure in selected environmental contexts is likely to define not only the risk for disease but also the different clinical phenotypes. Advances in imaging and functional tests over the past decades have increasingly broadened the awareness of the wide spectrum of features potentially occurring in pulmonary sarcoidosis, while the evolution of diagnostic techniques in interventional pulmonology has increased the possibility of obtaining tissue characterization more easily, by means of ultrasound-guided tools and cryotechnology. However, histological proof is not always needed, as, in selected scenarios with compatible clinical and imaging picture, a confirmatory biopsy is perceived as redundant. The diagnostic workup should be tailored on a case-by-case basis, according to an integrated assessment of clinical features, local resources, and expertise availability. Owing to the heterogeneity of possible clinical scenarios and the paucity of evidence-based data on treatments, a standardized clinical management has yet to be established, and general approach usually reflects expert opinion from accumulated clinical data. Key elements of decision-making process are to assess the baseline severity of disease, to stratify the risk of progression, and to define the goals of treatment.
Funding
None.
-
References
- 1 Ramachandraiah V, Aronow W, Chandy D. Pulmonary sarcoidosis: an update. Postgrad Med 2017; 129 (01) 149-158
- 2 Kouranos V, Hansell DM, Sharma R, Wells AU. Advances in imaging of cardiopulmonary involvement in sarcoidosis. Curr Opin Pulm Med 2015; 21 (05) 538-545
- 3 Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest 2015; 147 (02) 438-449
- 4 Cozier YC. Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions. Eur Respir J 2016; 48 (06) 1545-1548
- 5 Liang NC, Truong KT, Afshar K. Key management considerations in sarcoidosis from the American Thoracic Society 2016 Conference. J Thorac Dis 2016; 8 (Suppl. 07) S569-S572
- 6 Kouranos V, Jacob J, Wells AU. Severe sarcoidosis. Clin Chest Med 2015; 36 (04) 715-726
- 7 Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med 2012; 41 (6, Pt 2): e289-e302
- 8 Judson MA. Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. Expert Rev Respir Med 2017; 11 (02) 111-118
- 9 Walsh SL, Wells AU, Sverzellati N. , et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2 (02) 123-130
- 10 Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016; 48 (06) 1690-1699
- 11 Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946-2013: a population-based study. Mayo Clin Proc 2016; 91 (02) 183-188
- 12 Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo Jr CA. Epidemiology of sarcoidosis in a prospective cohort study of U.S. women. Ann Am Thorac Soc 2016; 13 (01) 67-71
- 13 Ungprasert P, Crowson CS, Matteson EL. Seasonal variation in incidence of sarcoidosis: a population-based study, 1976-2013. Thorax 2016; thoraxjnl-2016-209032
- 14 Sawahata M, Sugiyama Y. An epidemiological perspective of the pathology and etiology of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (02) 112-116
- 15 Sawahata M, Sugiyama Y, Nakamura Y. , et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med 2015; 109 (02) 272-278
- 16 Sawahata M, Sugiyama Y, Nakamura Y. , et al. Age-related differences in chest radiographic staging of sarcoidosis in Japan. Eur Respir J 2014; 43 (06) 1810-1812
- 17 Fingerlin TE, Hamzeh N, Maier LA. Genetics of sarcoidosis. Clin Chest Med 2015; 36 (04) 569-584
- 18 Sato H, Woodhead FA, Ahmad T. , et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet 2010; 19 (20) 4100-4111
- 19 Wennerström A, Pietinalho A, Vauhkonen H. , et al; Finnish Sarcoidosis Study Group. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis. Hum Immunol 2012; 73 (01) 93-100
- 20 Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003; 167 (09) 1225-1231
- 21 Spagnolo P, Renzoni EA, Wells AU. , et al. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. Am J Respir Crit Care Med 2005; 172 (06) 721-728
- 22 Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens 2010; 75 (03) 262-268
- 23 Wijnen PA, Cremers JP, Nelemans PJ. , et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014; 43 (06) 1730-1739
- 24 Sato H, Williams HR, Spagnolo P. , et al. CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. Eur Respir J 2010; 35 (02) 324-330
- 25 Veltkamp M, van Moorsel CH, Rijkers GT, Ruven HJ, Grutters JC. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens 2012; 79 (01) 25-32
- 26 Fischer A, Ellinghaus D, Nutsua M. , et al; GenPhenReSa Consortium. Identification of immune-relevant factors conferring sarcoidosis genetic risk. Am J Respir Crit Care Med 2015; 192 (06) 727-736
- 27 Fischer A, Nothnagel M, Franke A. , et al. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J 2011; 37 (03) 610-616
- 28 Heron M, van Moorsel CH, Grutters JC. , et al. Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens 2011; 77 (02) 112-117
- 29 Kruit A, Grutters JC, Ruven HJ. , et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006; 129 (06) 1584-1591
- 30 Mostard RL, Verschakelen JA, van Kroonenburgh MJ. , et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013; 107 (03) 439-447
- 31 Adams H, Keijsers RG, Korenromp IH, Grutters JC. FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med 2014; 35 (03) 352-361
- 32 Lockstone HE, Sanderson S, Kulakova N. , et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 2010; 181 (12) 1367-1375
- 33 Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18 (07) 1028-1040
- 34 Pechkovsky DV, Prasse A, Kollert F. , et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 2010; 137 (01) 89-101
- 35 Patterson KC, Hogarth K, Husain AN, Sperling AI, Niewold TB. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Transl Res 2012; 160 (05) 321-331
- 36 Miyara M, Amoura Z, Parizot C. , et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203 (02) 359-370
- 37 Chen ES, Song Z, Willett MH. , et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010; 181 (04) 360-373
- 38 Cinetto F, Agostini C. Advances in understanding the immunopathology of sarcoidosis and implications on therapy. Expert Rev Clin Immunol 2016; 12 (09) 973-988
- 39 Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996; 109 (05) 1276-1282
- 40 Miyoshi S, Hamada H, Kadowaki T. , et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010; 137 (06) 1391-1397
- 41 Janssen R, Sato H, Grutters JC. , et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest 2003; 124 (06) 2119-2125
- 42 Honda K, Okada F, Ando Y. , et al. Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoidosis. Br J Radiol 2011; 84 (999) 229-235
- 43 Xu X, Chen H, Zhu X. , et al. S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear factor-κB-dependent pathways. Clin Exp Immunol 2013; 173 (03) 523-535
- 44 Korthagen NM, Nagtegaal MM, van Moorsel CH, Kazemier KM, van den Bosch JM, Grutters JC. MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clin Exp Immunol 2010; 161 (02) 342-347
- 45 Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest 2009; 136 (05) 1371-1380
- 46 Carmona EM, Kalra S, Ryu JH. Pulmonary sarcoidosis: diagnosis and treatment. Mayo Clin Proc 2016; 91 (07) 946-954
- 47 Nunes H, Uzunhan Y, Gille T, Lamberto C, Valeyre D, Brillet PY. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir J 2012; 40 (03) 750-765
- 48 Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med 2016; 22 (05) 484-491
- 49 Martusewicz-Boros MM, Boros WP, Wiatr E, Wesolowski S, Roszkowski-Sliz K. Bronchial hyperreactivity in sarcoidosis patients: correlation with airflow limitation indices. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 99-106
- 50 Boros PW, Enright PL, Quanjer PH, Borsboom GJ, Wesolowski SP, Hyatt RE. Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J 2010; 36 (06) 1315-1322
- 51 Baughman RP. Sarcoidosis-associated pulmonary hypertension. Semin Respir Crit Care Med 2017; 38 (04) XX-XX
- 52 Harrison BD, Shaylor JM, Stokes TC, Wilkes AR. Airflow limitation in sarcoidosis--a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med 1991; 85 (01) 59-64
- 53 Lamberto C, Saumon G, Loiseau P, Battesti JP, Georges R. Respiratory function in recent pulmonary sarcoidosis with special reference to small airways. Bull Eur Physiopathol Respir 1985; 21 (04) 309-315
- 54 Burgel PR, Bourdin A, Chanez P. , et al. Update on the roles of distal airways in COPD. Eur Respir Rev 2011; 20 (119) 7-22
- 55 Goldman MD, Saadeh C, Ross D. Clinical applications of forced oscillation to assess peripheral airway function. Respir Physiol Neurobiol 2005; 148 (1-2): 179-194
- 56 Renzoni E, Karagiannis K, Bikov A. , et al. Impulse oscillometry is more tightly linked to symptoms and quality of life than conventional lung function measures in pulmonary sarcoidosis. Am J Respir Crit Care Med 2014; 189: A4078
- 57 Tanizawa K, Handa T, Nagai S. , et al. Comprehensive evaluation of airway involvement in pulmonary sarcoidosis. ERJ Open Res 2017; 3 (01) 00105-02016
- 58 Gasparini S, Bonifazi M. Cryobiopsy for interstitial lung diseases. J Bronchology Interv Pulmonol 2016; 23 (01) 4-6
- 59 Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of conventional transbronchial needle aspiration in sarcoidosis: a systematic review and meta-analysis. Respir Care 2013; 58 (04) 683-693
- 60 Vorselaars AD, Crommelin HA, Deneer VH. , et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 2015; 46 (01) 175-185
- 61 Cremers JP, Van Kroonenburgh MJ, Mostard RL. , et al. Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 37-45
- 62 Culver DA. Diagnosing sarcoidosis. Curr Opin Pulm Med 2015; 21 (05) 499-509
- 63 Nagai S, Izumi T. Bronchoalveolar lavage. Still useful in diagnosing sarcoidosis?. Clin Chest Med 1997; 18 (04) 787-797
- 64 Shen Y, Pang C, Wu Y. , et al. Diagnostic performance of bronchoalveolar lavage fluid CD4/CD8 ratio for sarcoidosis: a meta-analysis. EBioMedicine 2016; 8: 302-308
- 65 Mondoni M, Radovanovic D, Valenti V, Patella V, Santus P. Bronchoscopy in sarcoidosis: union is strength. Minerva Med 2015; 106 (02) (Suppl. 02) 1-7
- 66 Kocoń P, Szlubowski A, Kużdżał J. , et al. Endosonography-guided needle aspiration in the diagnosis of sarcoidosis - randomized study. Pol Arch Med Wewn 2017; 127 (03) 154-162
- 67 Li K, Jiang S. A randomized controlled study of conventional TBNA versus EBUS-TBNA for diagnosis of suspected stage I and II sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (03) 211-218
- 68 Gupta D, Dadhwal DS, Agarwal R, Gupta N, Bal A, Aggarwal AN. Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest 2014; 146 (03) 547-556
- 69 Gasparini S. It is time for this ‘ROSE’ to flower. Respiration 2005; 72 (02) 129-131
- 70 Bonifazi M, Sediari M, Ferretti M. , et al. The role of the pulmonologist in rapid on-site cytologic evaluation of transbronchial needle aspiration: a prospective study. Chest 2014; 145 (01) 60-65
- 71 Plit ML, Havryk AP, Hodgson A. , et al. Rapid cytological analysis of endobronchial ultrasound-guided aspirates in sarcoidosis. Eur Respir J 2013; 42 (05) 1302-1308
- 72 Raghu G, Collard HR, Egan JJ. , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (06) 788-824
- 73 Tomassetti S, Wells AU, Costabel U. , et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 193 (07) 745-752
- 74 Ravaglia C, Bonifazi M, Wells AU. , et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration 2016; 91 (03) 215-227
- 75 Chopra A, Judson MA. How are cancer and connective tissue diseases related to sarcoidosis?. Curr Opin Pulm Med 2015; 21 (05) 517-524
- 76 Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol 2007; 25 (03) 326-333
- 77 Bonifazi M, Bravi F, Gasparini S. , et al. Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies. Chest 2015; 147 (03) 778-791
- 78 Newman LS, Rose CS, Bresnitz EA. , et al; ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170 (12) 1324-1330
- 79 Valeyre D, Soler P, Clerici C. , et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax 1988; 43 (07) 516-524
- 80 Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2013; 41 (03) 621-626
- 81 Denning DW, Cadranel J, Beigelman-Aubry C. , et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47 (01) 45-68
- 82 Desai SR, Hedayati V, Patel K, Hansell DM. Chronic aspergillosis of the lungs: unravelling the terminology and radiology. Eur Radiol 2015; 25 (10) 3100-3107
- 83 Stevens DA, Kan VL, Judson MA. , et al; Infectious Diseases Society of America. Practice guidelines for diseases caused by Aspergillus . Clin Infect Dis 2000; 30 (04) 696-709
- 84 Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test?. Semin Respir Crit Care Med 2010; 31 (04) 409-418
- 85 Nam HS, Jeon K, Um SW. , et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010; 14 (06) e479-e482
- 86 Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (02) 91-107